Coming Soon

Relapsed and Refractory CLL, SLL, and Select Low-grade Lymphomas Treatment Study

In this study, we are looking at a medicine called ZE50-0134 that might help treat people with relapsed and refractory CLL, SLL, or certain low-grade lymphomas. We want to see if taking different amounts of this medicine in capsule form is safe for patients.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Deborah Stephens
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Lymphoma)

IRB Number

25-0277

ClinicalTrials.gov

NCT06708897

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.